NCT05132985View on ClinicalTrials.gov

Neoadjuvant Icotinib With Chemotherapy for Epidermal Growth Factor Receptor(EGFR)-Mutated Resectable Lung Adenocarcinoma

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

January 1, 2022

Primary Completion Date

July 1, 2024

Study Completion Date

January 1, 2028

Conditions
NSCLCEGF-R Positive Non-Small Cell Lung Cancer
Interventions
DRUG

Icotinib

125mg 1tt(Take 1 tablet 3 times a day) orally.

DRUG

Cisplatin

75 mg/m2 (IV，Q3W)

DRUG

Carboplatin

AUC 5 (IV, Q3W)

DRUG

Pemetrexed

500 mg/m2 (IV, Q3W)

Trial Locations (1)

110000

Liaoning Cancer Hospital & Institute, Shenyang

All Listed Sponsors
lead

Liaoning Cancer Hospital & Institute

OTHER